And, you will recall that if you look at the What we just put out the 24 respiratory revenue guidance, 4.60 to 7.30. So if you pull out an estimate for low end of the range for COVID, you pull out an estimate for RSV and strep that's consistent with 2023 and you pull out the $30,000,000 to $50,000,000 of Savanna, you're going to get a flu range that now is about $160,000,000 to $360,000,000 And that compares to the $230,000,000 to $270,000,000 that we gave for 2023. So we have in response to what happened in Q4, we are widening the range on the low and high end, so we don't miss and we've included a realistic high end that is possible. And that's the 40,000,000 to 60,000,000 And if you think about sort of historical where that $40,000,000 to $50,000,000 sits, in Q4 'twenty three, It was a $50,000,000 or $50,000,000 sorry, dollars 50,000,000 test market size market. And that compares to Q4 'twenty two with a 57,000,000 size market.